Ubs Group Ag Aclaris Therapeutics, Inc. Call Options Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ACRS
# of Institutions
97Shares Held
52.4MCall Options Held
32.4KPut Options Held
3.3K-
Bml Capital Management, LLC Zionsville, IN13MShares$27.1 Million10.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.69MShares$9.8 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.34MShares$6.97 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.32MShares$6.94 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.75MShares$5.75 Million0.09% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $139M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...